Combating resistance while maintaining innovation: The future of antimicrobial stewardship

Richard J. Vickers, Matteo Bassetti, Cornelius J. Clancy, Kevin W. Garey, David E. Greenberg, Minh Hong Nguyen, David Roblin, Glenn S. Tillotson, Mark H. Wilcox

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Antimicrobial resistance represents a significant global health threat. However, a commercial model that does not offer a return on investment resulting in a lack of investment in antibiotic R&D, means that the current pipeline of antibiotics lacks sufficient innovation to meet this challenge. Those responsible for defining, promoting and monitoring the rationale use of antibiotics (the antimicrobial stewardship programme) are key to addressing current shortcomings. In this personal perspective, we discuss the future role stewardship can play in stimulating innovation, a need to move away from a pharmacy budget dominated view of antibiotic use, and the impact of the ever-increasing sophistication and interdisciplinary nature of antimicrobial control programs. Changes are needed to optimize clinical outcomes for patients.

Original languageEnglish (US)
Pages (from-to)1331-1341
Number of pages11
JournalFuture Microbiology
Issue number15
StatePublished - 2019


  • antibiotic cost
  • antimicrobial stewardship
  • novel mechanism antibiotics

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Combating resistance while maintaining innovation: The future of antimicrobial stewardship'. Together they form a unique fingerprint.

Cite this